37 articles with Roche Group
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
Collaboration Will Advance Comprehensive Genomic Profiling, Clinical Trials and Real-World Data Studies for Cancer Patients
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection.
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
Blueprint Medicines and Genentech, a member of the Roche Group, to co-commercialize pralsetinib and equally share profits in the U.S.
FDA Grants Breakthrough Therapy Designation for Genentech’s Esbriet (pirfenidone) in Unclassifiable Interstitial Lung Disease
The designation is based on results from a Phase II trial, which suggested Esbriet slowed disease progression in patients with uILD at 24 weeks
Ningbo NewBay Medical Technology Co., Ltd. announced that it has entered into a licensing agreement with Genentech, a member of the Roche Group, under which it has been granted the exclusive global rights to further develop and commercialize GDC-0570, a small molecule Pan-PIM inhibitor that is active against multiple myeloma and prostate cancer in preclinical models.
Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-invasive Urothelial Cancer
Genentech, a member of the Roche Group, announced that the Phase III IMvigor010 study evaluating Tecentriq® as an adjuvant monotherapy treatment did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer.
Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular Carcinoma
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer
Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer
Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact With an Infected Person by 86 Percent
Genentech, a member of the Roche Group, announced that the Phase III BLOCKSTONE study showed preventive treatment with Xofluza™ after exposure to an infected household member significantly reduced the risk of people developing the flu by 86 percent versus placebo.
Genentech Presents Positive Phase III Study Results for One-dose Xofluza (Baloxavir Marboxil) in Children With the Flu
Genentech, a member of the Roche Group, announced that the Phase III MINISTONE-2 study showed that one-dose Xofluza™ was a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years old.
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain
Genentech’s Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer
Convelo Therapeutics Enters Into Collaboration and Option to Acquire Agreement With Genentech to Discover Novel Remyelinating Therapies
The collaboration will build on the remyelinating targets and proprietary screening platform developed by Convelo’s scientific founders Drs Paul Tesar and Drew Adams.
Clover Health Launches Clover Therapeutics, a New Research Subsidiary to Develop Treatment for Chronic Diseases
Newly inked research collaboration and license agreement with Genentech aims to better understand the genetics of ocular diseases
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
The MINISTONE-2 study showed XOFLUZA, given as a new oral suspension, is a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years
Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
Genentech, a member of the Roche Group, announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV).
Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
Genentech, a member of the Roche Group, announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva® for adults with proliferative lupus nephritis.
Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales
Genentech announced that the Phase III BLOCKSTONE study, conducted by Shionogi & Co., Ltd., met its primary endpoint showing that people exposed to a household member with influenza and treated preventatively with XOFLUZA™ were significantly less likely to develop the disease compared to those treated with placebo.